Goelzer Funding Administration Inc. lowered its place in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.6% throughout the third quarter, in accordance with the corporate in its most up-to-date 13F submitting with the SEC. The fund owned 52,647 shares of the corporate’s inventory after promoting 326 shares throughout the quarter. Goelzer Funding Administration Inc.’s holdings in AbbVie have been value $10,397,000 as of its most up-to-date submitting with the SEC.
A number of different giant buyers additionally lately modified their holdings of the corporate. jvl associates llc purchased a brand new place in shares of AbbVie throughout the third quarter value roughly $217,000. First Residents Monetary Corp grew its holdings in AbbVie by 0.9% within the third quarter. First Residents Monetary Corp now owns 5,777 shares of the corporate’s inventory value $1,141,000 after buying a further 53 shares throughout the interval. Duncan Williams Asset Administration LLC elevated its stake in AbbVie by 135.9% within the third quarter. Duncan Williams Asset Administration LLC now owns 4,260 shares of the corporate’s inventory valued at $841,000 after buying a further 2,454 shares within the final quarter. Abacus Wealth Companions LLC raised its holdings in shares of AbbVie by 14.9% throughout the third quarter. Abacus Wealth Companions LLC now owns 1,737 shares of the corporate’s inventory valued at $343,000 after buying a further 225 shares throughout the interval. Lastly, Apella Capital LLC boosted its place in shares of AbbVie by 6.6% throughout the third quarter. Apella Capital LLC now owns 8,070 shares of the corporate’s inventory value $1,588,000 after buying a further 501 shares within the final quarter. 70.23% of the inventory is at present owned by institutional buyers and hedge funds.
AbbVie Inventory Efficiency
Shares of NYSE ABBV traded down $1.16 throughout mid-day buying and selling on Friday, reaching $194.29. 4,749,856 shares of the corporate’s inventory have been exchanged, in comparison with its common quantity of 5,336,546. The agency has a 50-day transferring common value of $193.35 and a two-hundred day transferring common value of $176.85. The corporate has a debt-to-equity ratio of 8.51, a present ratio of 0.81 and a fast ratio of 0.71. The agency has a market capitalization of $343.09 billion, a price-to-earnings ratio of 57.65, a price-to-earnings-growth ratio of two.65 and a beta of 0.63. AbbVie Inc. has a 52 week low of $135.85 and a 52 week excessive of $199.95.
AbbVie (NYSE:ABBV – Get Free Report) final issued its quarterly earnings outcomes on Thursday, July twenty fifth. The corporate reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.08. AbbVie had a web margin of 9.71% and a return on fairness of 203.66%. The corporate had income of $14.46 billion throughout the quarter, in comparison with analyst estimates of $14.02 billion. Throughout the identical quarter final 12 months, the enterprise posted $2.91 EPS. AbbVie’s quarterly income was up 4.3% in comparison with the identical quarter final 12 months. Analysts predict that AbbVie Inc. will submit 10.86 EPS for the present 12 months.
AbbVie Dividend Announcement
The corporate additionally lately declared a quarterly dividend, which shall be paid on Friday, November fifteenth. Stockholders of report on Tuesday, October fifteenth shall be given a dividend of $1.55 per share. The ex-dividend date of this dividend is Tuesday, October fifteenth. This represents a $6.20 dividend on an annualized foundation and a dividend yield of three.19%. AbbVie’s dividend payout ratio is presently 183.98%.
Insider Shopping for and Promoting
In different information, Chairman Richard A. Gonzalez bought 66,500 shares of the enterprise’s inventory in a transaction that occurred on Monday, August fifth. The shares have been bought at a mean value of $186.52, for a complete worth of $12,403,580.00. Following the sale, the chairman now owns 446,599 shares of the corporate’s inventory, valued at $83,299,645.48. The commerce was a 0.00 % lower of their possession of the inventory. The transaction was disclosed in a doc filed with the SEC, which is out there at the SEC web site. In different information, Chairman Richard A. Gonzalez bought 282,845 shares of the corporate’s inventory in a transaction dated Wednesday, July seventeenth. The inventory was bought at a mean value of $175.00, for a complete transaction of $49,497,875.00. Following the sale, the chairman now straight owns 513,099 shares within the firm, valued at $89,792,325. This represents a 0.00 % lower of their possession of the inventory. The sale was disclosed in a submitting with the SEC, which is out there at this hyperlink. Additionally, Chairman Richard A. Gonzalez bought 66,500 shares of the agency’s inventory in a transaction that occurred on Monday, August fifth. The shares have been bought at a mean value of $186.52, for a complete transaction of $12,403,580.00. Following the completion of the transaction, the chairman now owns 446,599 shares of the corporate’s inventory, valued at $83,299,645.48. This commerce represents a 0.00 % lower of their possession of the inventory. The disclosure for this sale might be discovered right here. 0.25% of the inventory is at present owned by insiders.
Wall Avenue Analyst Weigh In
Numerous brokerages lately commented on ABBV. Morgan Stanley boosted their goal value on AbbVie from $211.00 to $218.00 and gave the corporate an “chubby” ranking in a analysis report on Monday, August twelfth. Barclays upped their goal value on AbbVie from $187.00 to $200.00 and gave the inventory an “chubby” ranking in a analysis report on Friday, July twenty sixth. Wells Fargo & Firm lifted their value goal on shares of AbbVie from $200.00 to $205.00 and gave the corporate an “chubby” ranking in a analysis report on Friday, July twenty sixth. Cantor Fitzgerald restated an “chubby” ranking and set a $200.00 value goal on shares of AbbVie in a report on Monday, August fifth. Lastly, Piper Sandler Corporations reiterated an “chubby” ranking and set a $190.00 value goal on shares of AbbVie in a report on Wednesday, July third. Two analysts have rated the inventory with a maintain ranking, twelve have assigned a purchase ranking and two have assigned a robust purchase ranking to the corporate’s inventory. Based on MarketBeat.com, the corporate has a consensus ranking of “Purchase” and a mean goal value of $191.64.
View Our Newest Inventory Evaluation on ABBV
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells prescription drugs worldwide. The corporate affords Humira, an injection for autoimmune and intestinal Behçet’s ailments, and pyoderma gangrenosum; Skyrizi to deal with average to extreme plaque psoriasis, psoriatic illness, and Crohn’s illness; Rinvoq to deal with rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn’s illness; Imbruvica for the remedy of grownup sufferers with blood cancers; Epkinly to deal with lymphoma; Elahere to deal with most cancers; and Venclexta/Venclyxto to deal with blood cancers.
Featured Tales
Need to see what different hedge funds are holding ABBV? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Obtain Information & Rankings for AbbVie Day by day – Enter your electronic mail tackle beneath to obtain a concise every day abstract of the most recent information and analysts’ scores for AbbVie and associated firms with MarketBeat.com’s FREE every day electronic mail e-newsletter.